146 results on '"Ballas, M."'
Search Results
2. EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
3. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
4. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
5. Numerical Simulation of Three-Dimensional Complex Flows Using a Pressure-Based Non-Staggered Grid Method
6. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
7. Effect of thermal conductivity on reaction front propagation during combustion synthesis of intermetalics
8. Surface tension effects on the nonlinear behavior of long waves in a two layer flow
9. Rapid Desensitization Did Not Prevent Febrile “Idiosyncratic” Reactions to Oxaliplatin: 750
10. 951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis
11. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer
12. 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
13. 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
14. Effect of Geography and Climate on Pain Frequency in Patients Enrolled in the Muticenter Study of Hydroxyurea in Sickle Cell Anemia: # 253
15. HLA-B☆3531, a hybrid of B35 and B61, implications for diagnostic approaches to alleles with complex ancestral compositions
16. Characterization of the novel allele HLA-B*4417: implications for bone marrow transplantation
17. Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
18. P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
19. Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
20. HLA class I and class II of the Nivkhi, an indigenous population carrying HTLV-I in Sakhalin, Far Eastern Russia
21. THE AMINO TERMINUS OF ALZHEIMER'S β-AMYLOID PEPTIDE CONTAINS AN ESSENTIAL EPITOPE FOR MAINTAINING AND RESTORING ITS SOLUBILITY
22. First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1
23. Abstract OT3-06-07: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer
24. Generation and characterization of three new monoclonal antibodies detecting the allospecificities HLA-A2, w69, HLA-A3 and HLA-B13
25. 1971P - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
26. 1119PD - Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
27. 1138PD - First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1
28. A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of Medi4736 in Patients with Locally Advanced, Unresectable, Stage 3 Nsclc Who Have not Progressed Following Platinum-Based, Concurrent Chemoradiation Therapy (PACIFIC)
29. Phase 2, Open-Label, International, Non-Comparative Study of MEDI4736 in Patients with Locally Advanced or Metastatic, Pd-L1 +, Stage 3B–4 Nsclc Who Have Received ≥2 Prior Systemic Treatment Regimens (ATLANTIC)
30. Usuario policonsultante: Estrategia de manejo para equipos de APS
31. Mapping of an HLA-DRw52-associated determinant on DRβ1 molecules
32. Alloreactive T-cell clones raised in an HLA-B/D crossing-over family dissect HLA-DR5 and HLA-DQw3 subtypes
33. The Allelic Determinants HLA-DR3 and HLA-DR5 and the Supertypic Determinant HLA-DRw52 May Be Located on the Same DRβ Chain
34. A Phase 2, Non-Comparative, Open-Label, International Study of MEDI4736 in Patients with Locally Advanced or Metastatic PD-L1-Positive NSCLC (Stage IIIB-IV) Who have Received ≥ 2 Prior Systemic Treatment Regimens (Atlantic)
35. A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of MEDI4736 in Patients with Locally Advanced, Unresectable NSCLC (Stage III) Who have not Progressed following Platinum-Based, Concurrent Chemoradiation Therapy (Pacific)
36. A Phase 2, Non-Comparative, Open-Label, Multicenter, International Study of Medi4736 in Patients with Locally Advanced or Metastatic Pd-L1-Positive Nsclc (Stage Iiib-Iv) Who Have Received ≥ 2 Prior Systemic Treatment Regimens, Including a Platinum-Based Chemotherapy (Atlantic)
37. Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)
38. CLINICAL TRIALS
39. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).
40. HLA-DR beta chain residues that are predicted to be located in the floor of the peptide-binding groove contribute to antibody-binding epitopes
41. A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors
42. An automated data management/analysis system for space shuttle orbiter tiles
43. Generation and characterization of three new monoclonal antibodies detecting the allospecificities HLA-A2, w69, HLA-A3 and HLA-B13
44. Allorecognition and T cell repertoire selection in severe combined immunodeficiency lacking HLA class II antigens
45. Prognostic significance of clinical features and Akt activation in the survival of patients with bronchioloalveolar carcinoma (BAC)
46. A non-destructive high-voltage low-energy intermittent fault location system.
47. 17TiP - A Phase 2, Non-Comparative, Open-Label, International Study of MEDI4736 in Patients with Locally Advanced or Metastatic PD-L1-Positive NSCLC (Stage IIIB-IV) Who have Received ≥ 2 Prior Systemic Treatment Regimens (Atlantic)
48. 16TiP - A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of MEDI4736 in Patients with Locally Advanced, Unresectable NSCLC (Stage III) Who have not Progressed following Platinum-Based, Concurrent Chemoradiation Therapy (Pacific)
49. 1335TiP - A Phase 2, Non-Comparative, Open-Label, Multicenter, International Study of Medi4736 in Patients with Locally Advanced or Metastatic Pd-L1-Positive Nsclc (Stage Iiib-Iv) Who Have Received ≥ 2 Prior Systemic Treatment Regimens, Including a Platinum-Based Chemotherapy (Atlantic)
50. A Hybrid Constitutive Model for Semi-Solid Alloy Slurries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.